Search Medical Condition
Please enter condition
Please choose location
 

Lynwood, California Clinical Trials

A listing of Lynwood, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (931) clinical trials

ATR Kinase Inhibitor VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ATR kinase inhibitor VX-970 (VX-970) in combination with irinotecan hydrochloride (irinotecan) in patients with advanced solid tumors. SECONDARY OBJECTIVES: I. To estimate the safety and tolerability of VX-970 in combination with irinotecan. II. ...

Phase

8.18 miles

Learn More »

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Primary Objective To determine the anti-tumor efficacy of brentuximab vedotin in relapsed/ refractory NSGCT. Secondary Objectives To determine the progression free survival in patients with relapsed/ refractory NSGCT treated with brentuximab vedotin. To determine the overall survival of patients with relapsed/ refractory NSGCT treated with brentuximab vedotin. To determine the ...

Phase

8.18 miles

Learn More »

Registry of Outcomes From AntiReflux Surgery

This is a prospective, multi center, observational database of patients that are having surgical laparoscopic antireflux procedure and/or hiatal hernia repair, including laparoscopic Nissen fundoplication and Magnetic Sphincter Augmentation with the LINX device. Patients meeting registry inclusion and exclusion will be followed for 5 years with standardized quality of life ...

Phase N/A

8.18 miles

Learn More »

Exercise Program During Chemotherapy in Metastatic Colorectal Cancer

PRIMARY OBJECTIVES: I. To determine whether a 6-week indoor or outdoor aerobic exercise program is feasible in patients with metastatic colorectal cancer (mCRC) undergoing chemotherapy and to explore patient's preferences for indoor versus (vs.) outdoor exercise. II. To determine the effects of a 6-week indoor or outdoor aerobic exercise program ...

Phase N/A

8.18 miles

Learn More »

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

PRIMARY OBJECTIVES: I. To determine the safety and tolerability of erlotinib hydrochloride (erlotinib) and onalespib lactate (onalespib) in patients with EGFR-mutant non-small cell lung cancer (NSCLC). (PHASE I) II. To preliminarily assess efficacy of combination erlotinib and onalespib at the recommended phase II dose (RP2D) determined in the phase I ...

Phase

8.18 miles

Learn More »

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

This will be a multi-center, global, open-label study in adult suffering from fluctuating Parkinson's disease subjects who have successfully completed the core study IN 11 004. After signing informed consent and meeting inclusion/exclusion criteria, eligible subjects will be enrolled into a 12-month open-label extension and receive the AP-CD/LD as needed. ...

Phase

8.18 miles

Learn More »

NK Cell Activity in Smokers Screened for Lung Cancer

Lung cancer is the leading cause of cancer mortality in the United States. Despite considerable clinical research in multi-modality cancer treatment, there has been no significant decrease in lung cancer-specific mortality over the past three decades. The recent results of the National Lung Screening Trial (NLST) established that screening high-risk ...

Phase N/A

8.18 miles

Learn More »

Evaluation of the Refugee Family Strengthening (RFS) Program

The US Committee for Refugees and Immigrants (USCRI) will be conducting an evaluation of a healthy marriage and relationship program developed by USCRI titled Refugee Family Strengthening (RFS) Program. This program is funded through an initiative of the Administration for Children and Families, Office of Family Assistance (OFA). The Refugee ...

Phase N/A

8.18 miles

Learn More »

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

PRIMARY OBJECTIVES: I. To determine the complete hematologic response (CR)/complete response incomplete (CRi) rate when sapanisertib (MLN0128 [TAK-228]) is administered to adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). SECONDARY OBJECTIVES: I. To determine the overall response rate (CR, CRi/partial response (PR)/morphologic leukemia free state [MLFS]). II. To determine the ...

Phase

8.18 miles

Learn More »

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

PRIMARY OBJECTIVES: I. To estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab. SECONDARY OBJECTIVES: I. To estimate event-free survival at ...

Phase

8.18 miles

Learn More »